OmniSeq News

OmniSeq, Inc. to Participate in the NCI-MATCH Clinical Trial

BUFFALO, N.Y., July 31, 2018 (GLOBE NEWSWIRE) -- OmniSeq, Inc.® a leading innovator in molecular science, today announced it is participating as a CLIA-certified/accredited laboratory for the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131) precision...

read more

OmniSeq & LabCorp Launch OmniSeq Advance℠ Assay

New test combines both targeted therapy and immune-oncology biomarkers in a single test with 99% actionability, providing benefits for the treatment of patients and the development of new therapies.ASCO, CHICAGO, ILLINOIS – June 1, 2018 – OmniSeq® , a CAP accredited,...

read more

OmniSeq & LabCorp Launch Tumor-Only MSI NGS Assay

BUFFALO, NEW YORK – April 16, 2018 – OmniSeq®, a molecular diagnostics subsidiary of the Roswell Park Comprehensive Cancer Center, and LabCorp® (NYSE: LH), a leading global life sciences company, announced today the commercial launch of OmniSeq MSI NGS, a tumor-only,...

read more

Launch of Immune Report Card

BUFFALO, N.Y., June 14, 2017 (GLOBE NEWSWIRE) -- OmniSeq, an innovation of Roswell Park Cancer Institute, announced today the commercial launch of Immune Report Card SM, the first immune profiling test designed to help oncologists select the best mono and...

read more

Follow Us on Twitter

Cell proliferation is potentially a new biomarker of response to immune checkpoint inhibitors in NSCLC, and it is applicable to PD-L1 negative tumors. Many thanks to our academic collaborators for contributing their valuable samples and expertise!

https://t.co/aJxMnQVn62

Congratulations to OmniSeq's Antonios Papanicolau-Sengos et al. for publishing their promising research on the use of RNA-Seq to put forth novel immunotherapy targets in sarcoma #rna #immunotherapy

https://t.co/X8bhd3miEM

OmniSeq is proud to contribute to the real world evidence for the clinical utility of #NGS testing

https://t.co/iVSuS3LZab

Excited to publish in "The Prostate" with our collaborators from Roswell Park Comprehensive Cancer Center and University of California San Diego on how RNA-seq can be used to identify novel checkpoint inhibition targets #checkpoint #rna

https://t.co/pdwyyEZFnP

Dr. Sean Glenn speaking in packed house at #SITC2018 on microsatellite instability by (NGS) Next Generation Sequencing.

2
Load More...